Corvus Pharmaceuticals, Inc.

We are a clinical stage biopharmaceutical company developing product candidates that precisely target proteins critical to immune cell maturation and function. Our proprietary product candidates are designed to address immune mediated diseases, inflammatory diseases, and cancers. Our lead product candidate, soquelitinib (formerly CPI-818), specifically binds to interleukin 2 inducible T cell kinase (ITK), a protein involved in T cell activation, T cell receptor signaling, and T cell differentiation and function. We believe soquelitinib can inhibit the production of inflammatory cytokines involved in diseases such as atopic dermatitis, hidradenitis suppurativa, asthma, psoriasis, and fibrotic diseases. Preclinical studies showed soquelitinib affected T cell differentiation, enhancing the function of T cells involved in tumor cell eradication. Soquelitinib is in a registrational, Phase 3 clinical trial for relapsed T cell lymphomas and a recently initiated randomized, placebo-controlled Phase 2 trial in patients with atopic dermatitis. We have two additional product candidates in clinical development for various solid tumors, also based on modulating immune function. Soquelitinib (CPI-818) is an investigational selective, orally bioavailable, covalent inhibitor of ITK.